News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The transaction is anticipated to close in the first quarter of 2022
The company's sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Subscribe To Our Newsletter & Stay Updated
